Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.

Lafage-Pochitaloff M, Baranger L, Hunault M, Cuccuini W, Lefebvre C, Bidet A, Tigaud I, Eclache V, Delabesse E, Bilhou-Nabéra C, Terré C, Chapiro E, Gachard N, Mozziconacci MJ, Ameye G, Porter S, Grardel N, Béné MC, Chalandon Y, Graux C, Huguet F, Lhéritier V, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Blood. 2017 Oct 19;130(16):1832-1844. doi: 10.1182/blood-2017-05-783852. Epub 2017 Aug 8.

PMID:
28790105
2.

Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature.

Quintela A, Sujobert P, Tigaud I, Hayette S, Ffrench M, Salles G, Thomas X, Plesa A.

Oncol Ther. 2017;5(1):111-118. doi: 10.1007/s40487-017-0041-7. Epub 2017 Feb 9.

3.

TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo A, Mortreux F, Wattel E.

Leuk Res. 2017 May;56:21-28. doi: 10.1016/j.leukres.2017.01.012. Epub 2017 Jan 16.

PMID:
28167452
4.

Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia.

Heiblig M, Paubelle E, Plesa A, Geay MO, Manzoni D, Gazzo S, Tigaud I, Callet-Bauchu E, Huet S, Salles G, Thomas X, Hayette S, Sujobert P.

Blood. 2017 Jan 5;129(1):128-131. doi: 10.1182/blood-2016-09-741355. Epub 2016 Nov 8. No abstract available.

PMID:
27827828
5.

Cytogenetic place in managing myelodysplastic syndromes: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Eclache V, Lafage-Pochitaloff M, Lefebvre C, Penther D, Raynaud S, Tigaud I.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):525-534. Review.

PMID:
27546835
6.

Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience.

Heiblig M, Le Jeune C, Elhamri M, Balsat M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Nicolini F, Wattel E, Salles G, Thomas X.

Leuk Lymphoma. 2017 Jan;58(1):110-117. Epub 2016 May 17.

PMID:
27184036
7.

Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience.

Heiblig M, Elhamri M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Michallet M, Nicolini F, Plesa C, Wattel E, Salles G, Thomas X.

Mediterr J Hematol Infect Dis. 2016 Jan 1;8(1):e2016009. doi: 10.4084/MJHID.2016.009. eCollection 2016.

8.

Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia.

Fattoum J, Cannas G, Elhamri M, Tigaud I, Plesa A, Heiblig M, Plesa C, Wattel E, Thomas X.

Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):477-83. doi: 10.1016/j.clml.2015.02.022. Epub 2015 Mar 5.

PMID:
25843415
9.

Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL.

Bond J, Bergon A, Durand A, Tigaud I, Thomas X, Asnafi V, Spicuglia S, Macintyre E.

Blood. 2014 Nov 6;124(19):3023-5. doi: 10.1182/blood-2014-04-567636. No abstract available.

10.

Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.

Huet S, Cony-Makhoul P, Heiblig M, Tigaud I, Gazzo S, Belhabri A, Souche D, Michallet M, Magaud JP, Hayette S, Nicolini F.

PLoS One. 2014 Sep 9;9(9):e106250. doi: 10.1371/journal.pone.0106250. eCollection 2014.

11.

Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia.

Plesa A, Elhamri M, Clapisson G, Mattei E, Gazzo S, Hequet O, Tigaud I, Michallet M, Dumontet C, Thomas X.

Leuk Lymphoma. 2015 Mar;56(3):622-9. doi: 10.3109/10428194.2014.927453. Epub 2014 Jul 17.

PMID:
24884314
12.

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy.

Etienne G, Dulucq S, Nicolini FE, Morisset S, Fort MP, Schmitt A, Etienne M, Hayette S, Lippert E, Bureau C, Tigaud I, Adiko D, Marit G, Reiffers J, Mahon FX.

Haematologica. 2014 Mar;99(3):458-64. doi: 10.3324/haematol.2013.095158. Epub 2013 Dec 20.

13.

Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.

Roux C, Nicolini FE, Rea D, Niault M, Mollica L, Berger F, Chassagne-Clément C, Tigaud I, Tulliez M, Giraudier S, Turhan A, Rousselot P, Legros L.

Blood. 2013 Oct 24;122(17):3082-4. doi: 10.1182/blood-2013-07-513879. No abstract available.

14.

Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature.

Chapiro E, Radford-Weiss I, Cung HA, Dastugue N, Nadal N, Taviaux S, Barin C, Struski S, Talmant P, Vandenberghe P, Mozziconacci MJ, Tigaud I, Lefebvre C, Penther D, Bastard C, Lippert E, Mugneret F, Romana S, Bernard OA, Harrison CJ, Russell LJ, Nguyen-Khac F; Groupe Francophone de Cytogénétique Hématologique.

Cancer Genet. 2013 May;206(5):162-73. doi: 10.1016/j.cancergen.2013.04.004. Epub 2013 Jul 1. Review.

PMID:
23827691
15.

Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia.

Boudry-Labis E, Roche-Lestienne C, Nibourel O, Boissel N, Terre C, Perot C, Eclache V, Gachard N, Tigaud I, Plessis G, Cuccuini W, Geffroy S, Villenet C, Figeac M, Leprêtre F, Renneville A, Cheok M, Soulier J, Dombret H, Preudhomme C; French ALFA group.

Am J Hematol. 2013 Apr;88(4):306-11. doi: 10.1002/ajh.23403. Epub 2013 Mar 5.

16.

High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia.

Hayette S, Thomas X, Jallades L, Chabane K, Charlot C, Tigaud I, Gazzo S, Morisset S, Cornillet-Lefebvre P, Plesa A, Huet S, Renneville A, Salles G, Nicolini FE, Magaud JP, Michallet M.

PLoS One. 2012;7(12):e51527. doi: 10.1371/journal.pone.0051527. Epub 2012 Dec 10.

17.

Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement.

Havelange V, Ameye G, Théate I, Callet-Bauchu E, Mugneret F, Michaux L, Dastugue N, Penther D, Barin C, Collonge-Rame MA, Baranger L, Terré C, Nadal N, Lippert E, Laï JL, Cabrol C, Tigaud I, Herens C, Hagemeijer A, Raphael M, Libouton JM, Poirel HA; GFCH (Groupe Francophone de Cytogénétique Hématologique).

Genes Chromosomes Cancer. 2013 Jan;52(1):81-92. doi: 10.1002/gcc.22008. Epub 2012 Sep 25.

PMID:
23012230
18.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association.

Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5.

PMID:
22482940
19.

PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.

Duhoux FP, Ameye G, Montano-Almendras CP, Bahloula K, Mozziconacci MJ, Laibe S, Wlodarska I, Michaux L, Talmant P, Richebourg S, Lippert E, Speleman F, Herens C, Struski S, Raynaud S, Auger N, Nadal N, Rack K, Mugneret F, Tigaud I, Lafage M, Taviaux S, Roche-Lestienne C, Latinne D, Libouton JM, Demoulin JB, Poirel HA; Groupe Francophone de Cytogénétique Hématologique (GFCH); Belgian Cytogenetic Group for Haematology and Oncology (BCG-HO).

Br J Haematol. 2012 Jan;156(1):76-88. doi: 10.1111/j.1365-2141.2011.08918.x. Epub 2011 Nov 3.

PMID:
22050763
20.

Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies.

Duhoux FP, Ameye G, Lambot V, Herens C, Lambert F, Raynaud S, Wlodarska I, Michaux L, Roche-Lestienne C, Labis E, Taviaux S, Chapiro E, Nguyen-Khac F, Struski S, Dobbelstein S, Dastugue N, Lippert E, Speleman F, Van Roy N, De Weer A, Rack K, Talmant P, Richebourg S, Mugneret F, Tigaud I, Mozziconacci MJ, Laibe S, Nadal N, Terré C, Libouton JM, Decottignies A, Vikkula M, Poirel HA; Groupe Francophone de Cytogénétique Hématologique (GFCH); Belgian Cytogenetic Group for Hematology and Oncology (BCG-HO).

PLoS One. 2011;6(10):e26311. doi: 10.1371/journal.pone.0026311. Epub 2011 Oct 21. Erratum in: PLoS One. 2011 Dec 13;6(12). doi: 10.1371/annotation/3b5aaa87-72b6-49d3-9ec9-f4a656e12e3a. Khac, Florence Nguyen [corrected to Nguyen-Khac, Florence].

Supplemental Content

Loading ...
Support Center